ArticleFrontiers in adolescent medicine2026
Cannabis use frequency may differentially impact cognitive performance in young adults with and without HIV.
Article in Frontiers in adolescent medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Introduction: Increased cannabis use in young adults may influence brain health and neurodevelopment. In the context of chronic HIV-associated neuroinflammation, however, mild cannabis use may attenuate negative outcomes through anti-inflammatory effects. More frequent cannabis use may remain deleterious to both young adults with HIV (YWH) and without HIV (YWoH). We explored cross-sectional associations between cannabis use frequency and cognitive performance in YWH and YWoH. Method: Participants aged 18-24 included 38 YWH and 61 YWoH (32% White) who completed cognitive tests of verbal memory, processing speed, working memory, executive functions, and overall fluid cognition. Timeline follow-back interviews assessed days of cannabis use (past 30, 180 and 365 days). Primary analyses focused on 30-day use, categorized as: no use, mild/moderate (1-<5 days used/week) and heavy (≥5 days used/week). Generalized estimating equations modeled associations of HIV, cannabis use category, and their interaction with cognitive outcomes; trend analyses used cannabis frequency as a continuous variable. Due to group differences in proportion of females, sex differences could not be addressed. Results: YWH had worse performance than YWoH in fluid cognition, memory, processing speed, and executive functioning. Adjusting for HIV status, heavy 30-day use, versus no use, was associated with worse performance on fluid cognition, immediate and delayed word list recall, processing speed and executive functions. Relative to mild/moderate use, heavy use was associated with worse immediate and delayed story recall and executive functions. Results were similar for 180- and 365-day use. Interactions between HIV status and 30-day cannabis use category were not significant, although exploratory analyses employing cannabis use as a continuous measure suggested a linear relationship for YWoH of greater use with worse cognitive performance, while for YWH, non-linear relationships suggested better performance with mild/moderate use on some memory and executive functioning measures. Conclusions: These results suggest ongoing heavy cannabis use is associated with worse cognitive performance among young adults. For YWH, however, mild to moderate levels of cannabis use may have a protective effect possibly through altering chronic neuroinflammation, although causality cannot be determined in this cross-sectional study. Understanding differential, population-specific effects of cannabis use frequency may be important in setting use guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.